Mode
Text Size
Log in / Sign up
Phase 3 N=10,160 Randomized Quadruple-blind Prevention

Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults

Virus Diseases · RNA Virus Infections · Respiratory Tract Diseases · Respiratory Tract Infections · Influenza

Enrolled (actual)
10,160
Serious AEs
1.1%
Results posted
Aug 2023
Primary outcome: Primary: Number of Occurrences of Protocol-Defined Respiratory Illness Caused by Vaccine-Matched Influenza Strains — 110; 169 Number of cases

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Quadrivalent VLP Vaccine (Biological); Placebo (Biological)
Age
Adult · 18+ yrs
Sex
All
Sponsor
Medicago
Primary completion
May 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Occurrences of Protocol-Defined Respiratory Illness Caused by Vaccine-Matched Influenza Strains
110; 169
SECONDARY
Number of Occurrences of Protocol-Defined Respiratory Illness Cases Caused by Any Laboratory Confirmed Influenza Strain
213; 347
SECONDARY
Number of Occurrences of Laboratory-Confirmed Protocol-Defined Influenza-Like Illness (ILI) Caused by Vaccine-Matched Influenza Strains
98; 148
SECONDARY
Number of Occurrences of Laboratory-Confirmed ILI Caused by Any Influenza Strain
178; 285
SECONDARY
Number of Occurrences of Protocol-Defined ILI Cases
1576; 1679
SECONDARY
Number of Participants With at Least One Immediate Complaint
441; 377
SECONDARY
Number of Participants With at Least One Solicited Local and Systemic Reactions
2776; 1723
SECONDARY
Number of Participants With ≥ Severe Solicited Local and Systemic Reactions
75; 85
SECONDARY
Number of Participants With ≥ Severe Related Solicited Reactions
56; 62
SECONDARY
Number of Participants With Unsolicited Treatment-Emergent Adverse Events (TEAEs)
661; 639
SECONDARY
Number of Participants With ≥ Severe Unsolicited TEAEs
13; 25
SECONDARY
Number of Participants With ≥ Severe Related Unsolicited Reactions
4; 6
SECONDARY
Number of Participants With an Occurrence of Death
1; 2
SECONDARY
Number of Participants With at Least One Serious TEAE
55; 51
SECONDARY
Number of Participants With at Least One AE Leading to Withdrawal
0; 5
SECONDARY
Number of Participants With at Least One New Onset Chronic Diseases (NOCDs)
54; 41
SECONDARY
Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response for Each Homologous and Heterologous Influenza Strain
24.2; 30.0; 84.8; 27.8; 26.2; 29.0
SECONDARY
Percentage of Participants With Seroconversion Measured by HI Antibody Response for Each Homologous and Heterologous Strain
37.1; 0; 46.4; 0; 17.6; 0
SECONDARY
Percentage of Participants With Seroprotection Measured by HI Antibody Response for Each Homologous and Heterologous Strain
40.6; 47.4; 74.8; 39.2; 46.4; 46.4
SECONDARY
Geometric Mean Fold Ratio (GMFR) of HI Antibody Response for Each Homologous and Heterologous Strain
3.4; 1.0; 5.5; 1.0; 2.2; 0.9
SECONDARY
GMTs of Microneutralization (MN) Antibody Response for Each Homologous Strain
88.1; 112.3; 366.1; 135.7; 46.7; 62.1
SECONDARY
Percentage of Participants With Seroconversion Measured by MN Antibody Response for Each Homologous Strain
41.7; 2.1; 28.1; 0; 30.6; 0
SECONDARY
GMFR of MN Antibody Response for Each Homologous Strain
4.0; 1.3; 2.5; 1.2; 2.5; 1.1
SECONDARY
Geometric Mean Area (GMA) of Single Radial Hemolysis (SRH) Antibody Response for Each Homologous Strain
10.3; 15.4; 31.4; 20.9; 15.6; 19.3
SECONDARY
Percentage of Participants With Seroconversion Measured by SRH Antibody Response for Each Homologous Strain
53.6; 14.4; 48.2; 14.4; 45.7; 9.3
SECONDARY
Percentage of Participants With Seroprotection Measured by SRH Antibody Response for Each Homologous Strain
36.3; 42.3; 75.9; 57.7; 54.7; 57.7
SECONDARY
GMFR of SRH Antibody Response for Each Homologous Strain
2.9; 1.6; 3.5; 1.6; 4.0; 1.3

Summary

This Phase 3 study is intended to assess the efficacy of the Quadrivalent VLP Influenza Vaccine during the 2017-2018 influenza season in healthy adults 18 to 64 years of age. One dose of Quadrivalent VLP Influenza Vaccine (30 μg/strain) or of placebo will be administered to approximately 10,000 participants

Eligibility Criteria

Inclusion Criteria

Participants must meet all of the following inclusion criteria to be eligible for participation in this study; no protocol waivers are allowed:

  • Participants must have a body mass index (BMI) below 40 kg/m^2;
  • Participants are considered by the Investigator to be reliable and likely to cooperate with the assessment procedures and be available for the duration of the study;
  • Participants must be in good general health prior to study participation, with no clinically relevant abnormalities that could jeopardize participant safety or interfere with study assessments, as assessed by the Principal Investigator or sub-Investigator (thereafter referred as Investigator) and determined by medical history, physical examination, and vital signs; Note: Participants with a pre-existing chronic disease will be allowed to participate if the disease is stable and, according to the Investigator's judgment, the condition is unlikely to confound the results of the study or pose additional risk to the participant by participating in the study. Stable disease is generally defined as no new onset or exacerbation of pre-existing chronic disease three months prior to vaccination. Based on the Investigator's judgment, a participant with more recent stabilization of a disease could also be eligible.
  • Female participants must have a negative urine pregnancy test result at the Screening/Vaccination visit (Visit 1).
  • Female participants of childbearing potential must use an effective method of contraception for one month prior to vaccination and agree to continue employing adequate birth control measures for at least 60 days post-vaccination. Moreover, female participants must have no plan to become pregnant for at least two months post-vaccination. Abstinent participants should be asked what method(s) they would use should their circumstances change, and participants without a well-defined plan should be excluded. The following relationship or methods of contraception are considered to be effective:
  • Hormonal contraceptives (e.g. oral, injectable, topical [patch], or estrogenic vaginal ring);
  • Intra-uterine device with or without hormonal release;
  • Male partner using a condom plus spermicide or sterilized partner (at least one year prior to vaccination);
  • Credible self-reported history of heterosexual vaginal intercourse abstinence until at least 60 days post-vaccination;
  • Female partner;
  • Non-childbearing females are defined as:
  • Surgically-sterile (defined as bilateral tubal ligation, hysterectomy or bilateral oophorectomy performed more than one month prior to vaccination); or
  • Post-menopausal (absence of menses for 24 consecutive months and age consistent with natural cessation of ovulation).

Exclusion Criteria

Participants who meet any of the following criteria will be excluded from participating in this study; no protocol waivers are allowed:

  • Any participant whose medical condition(s) is sufficiently severe that annual influenza vaccination would be routinely recommended in the jurisdiction of recruitment, as per the Investigator's judgement;
  • According to the Investigator's opinion, history of significant acute or chronic, uncontrolled medical or neuropsychiatric illness. 'Uncontrolled' is defined as:
  • Requiring a new medical or surgical treatment during the three months prior to study vaccine administration unless the criteria outlined in inclusion criterion no. 5 can be met (i.e. the Investigator can justify inclusion based upon the innocuous nature of medical/surgical events and/or treatments);
  • Requiring any significant change in a chronic medication (i.e. drug, dose, frequency) during the three months prior to study vaccine administration due to uncontrolled symptoms or drug toxicity unless the innocuous nature of the medication change meets the criteria outlined in inclusion criterion no. 5 and is appropriately justified by the Investigator.
  • Any medical or neuropsychiatric condition or
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03301051). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search